Developer docs
API playgroundTry for free, no card

Search company profiles

Oligo Medic

Full company profile

uuid0062t4h

Namestring
Oligo Medic
Legal namestring
Oligo Medic
Websiteurl
oligomedic.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Oligo Medic is a privately held Canadian biomaterials company headquartered in Laval, Quebec, founded in 2010 by biomaterials experts. The company specializes in functional biopolymers derived from chitosan and its derivatives, developing hydrogels, nanoparticles, photocuring materials, and bio-inks for biomedical applications with a focus on orthopedic use cases.

The company's core commercial asset is JointRep®, an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. JointRep® is approved by Australia's Therapeutic Goods Administration (TGA) and regulators in multiple other countries but is not currently available in the United States. A second product, LOMU®, is a viscosupplementation formulation positioned as a longer-residence-time alternative to hyaluronic acid injections and is in pre-clinical validation. Underlying these products is a broader chitosan-derivative technology platform spanning self-healing gels, polysaccharide-based nanoparticles for drug and genetic-material delivery, photocuring systems, and bio-inks for tissue engineering constructs.

Oligo Medic generates revenue primarily through medical device sales of JointRep® distributed via an established commercialization network covering more than 30 countries, supplemented by potential licensing of its proprietary biopolymer technologies derived from 25+ years of research. Go-to-market is executed through orthopedic-specialized field sales targeting surgeons, sports medicine physicians, and hospitals, supported by clinical evidence generation via the JMAC Study enrolling patients across Australia and Canada. Pricing is not publicly disclosed and operates on quote-based enterprise contracts with healthcare institutions.

Short descriptiontext

Oligo Medic is a Canadian biomaterials company that develops chitosan-based biopolymer technologies for orthopedic applications, commercializing the JointRep® injectable cartilage-repair hydrogel across 30+ countries while advancing the LOMU® viscosupplementation pipeline.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopolymer medical devices, chitosan biomaterials, cartilage repair hydrogel, viscosupplementation injection, orthopedic regenerative medicine
Industry2 codes
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthopedic Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Product Sales
TypeHardware Sales
Description

Sale of approved medical devices including JointRep® thermo-gel scaffold for cartilage repair. Commercialized through distribution network covering more than 30 countries.

oligomedic.com
2LOMU® Viscosupplementation (Pipeline)
TypeOne Time License
Description

Future viscosupplementation product for osteoarthritis treatment, currently in pre-clinical validation stage.

oligomedic.com
3Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary biopolymer technologies and formulations developed from 25+ years of research in chitosan derivatives for various biomedical applications.

oligomedic.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1JointRep
Description

Arthroscopically injectable hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedure for cartilage repair. Approved for use by Therapeutic Goods Administration in Australia and multiple other countries. Not currently available in the United States.

oligomedic.com
+1 more record
Core offering1 text field

Oligo Medic develops and commercializes chitosan-based biopolymer medical devices for orthopedic applications. Its marketed product, JointRep®, is an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. The company's pipeline includes LOMU®, a viscosupplementation formulation intended as a longer-residence-time alternative to hyaluronic acid injections for joint lubrication.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Cartilage defects occur in more than 900,000 injuries per year in the US alone
+1 more record
Product overview1 text field

Oligo Medic is a biomaterials company specializing in orthopedic applications of biopolymers, founded in 2010. The company offers a portfolio centered on chitosan-based technologies for cartilage repair and joint lubrication. The core marketed product is JointRep®, an injectable hydrogel scaffold for cartilage repair, while LOMU® is a pre-clinical viscosupplementation formulation. Underlying these products are proprietary technology platforms including Self-Healing Gel, Nanoparticles (for drug delivery), Photocuring, and Bio-ink, all built on chitosan biopolymer chemistry. The company operates across more than 30 countries through a commercialization network.

Product and service1 record
1JointRep®
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Anika produces hyaluronic acid-based viscosupplementation products (e.g., Monovisc, Orthovisc) for osteoarthritis joint lubrication. Direct competitor to Oligo Medic's pipeline LOMU® product, which is positioned as an alternative to HA injections.

TypeBroad incumbent
Description

Smith & Nephew is a major orthopedic medical device company with products across cartilage repair, sports medicine, and viscosupplementation. Their Regenaflex (hyaluronic acid) and broader sports medicine portfolio overlap with both JointRep® and LOMU® markets.

TypeDirect peer
Description

Bioventus markets DUROLANE and other HA-based viscosupplements for osteoarthritis treatment, plus orthopedic biologics for cartilage repair. Direct competitor across Oligo Medic's viscosupplementation and cartilage repair portfolio.

TypeDirect peer
Description

CartiHeal (acquired by Smith & Nephew) developed Agili-C, a cartilage repair scaffold for osteochondral lesions. Direct competitor to JointRep® in the cartilage regeneration scaffold market.

TypeBroad incumbent
Description

Stryker is a diversified orthopedic medical device leader with sports medicine and joint preservation products relevant to cartilage repair procedures. Larger incumbent operating broadly across Oligo Medic's target orthopedic segments.

TypeDirect peer
Description

Ferring markets EUFLEXXA (hyaluronic acid viscosupplement) for osteoarthritis knee pain. Direct competitor in the viscosupplementation space that LOMU® would target.

TypeDirect peer
Description

Vericel markets MACI (autologous chondrocyte implantation), the leading FDA-approved cartilage repair product. Direct competitor to Oligo Medic's JointRep® in the cartilage repair market, though addressing different procedural approaches (cell therapy vs. hydrogel scaffold-enhanced microfracture).

TypeBroad incumbent
Description

Sanofi markets Synvisc/Synvisc-One, one of the most widely used HA viscosupplementation brands globally. As a large incumbent in viscosupplementation, Sanofi represents the dominant commercial competitor that LOMU® would need to displace.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Oligo Medic

Orthopedic Medical Devicesoligomedic.com

Oligo Medic is a Canadian biomaterials company that develops chitosan-based biopolymer technologies for orthopedic applications, commercializing the JointRep® injectable cartilage-repair hydrogel across 30+ countries while advancing the LOMU® viscosupplementation pipeline.

What Oligo Medic does

Oligo Medic is a privately held Canadian biomaterials company headquartered in Laval, Quebec, founded in 2010 by biomaterials experts. The company specializes in functional biopolymers derived from chitosan and its derivatives, developing hydrogels, nanoparticles, photocuring materials, and bio-inks for biomedical applications with a focus on orthopedic use cases.

The company's core commercial asset is JointRep®, an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. JointRep® is approved by Australia's Therapeutic Goods Administration (TGA) and regulators in multiple other countries but is not currently available in the United States. A second product, LOMU®, is a viscosupplementation formulation positioned as a longer-residence-time alternative to hyaluronic acid injections and is in pre-clinical validation. Underlying these products is a broader chitosan-derivative technology platform spanning self-healing gels, polysaccharide-based nanoparticles for drug and genetic-material delivery, photocuring systems, and bio-inks for tissue engineering constructs.

Oligo Medic generates revenue primarily through medical device sales of JointRep® distributed via an established commercialization network covering more than 30 countries, supplemented by potential licensing of its proprietary biopolymer technologies derived from 25+ years of research. Go-to-market is executed through orthopedic-specialized field sales targeting surgeons, sports medicine physicians, and hospitals, supported by clinical evidence generation via the JMAC Study enrolling patients across Australia and Canada. Pricing is not publicly disclosed and operates on quote-based enterprise contracts with healthcare institutions.

Oligo Medic firmographics

Firmographics
Name
Oligo Medic
Legal name
Oligo Medic
Website
https://oligomedic.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
Oligo Medic is a Canadian biomaterials company that develops chitosan-based biopolymer technologies for orthopedic applications, commercializing the JointRep® injectable cartilage-repair hydrogel across 30+ countries while advancing the LOMU® viscosupplementation pipeline.
Ownership category
akta.pro rank

Oligo Medic industry classification

Industry
Product category
Orthopedic Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Biopolymer medical devices
  • Chitosan biomaterials
  • Cartilage repair hydrogel
  • Viscosupplementation injection
  • Orthopedic regenerative medicine

Where Oligo Medic is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Oligo Medic business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Medical Device Product Sales: Sale of approved medical devices including JointRep® thermo-gel scaffold for cartilage repair. Commercialized through distribution network covering more than 30 countries.
  2. LOMU® Viscosupplementation (Pipeline): Future viscosupplementation product for osteoarthritis treatment, currently in pre-clinical validation stage.
  3. Technology Licensing: Licensing of proprietary biopolymer technologies and formulations developed from 25+ years of research in chitosan derivatives for various biomedical applications.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Oligo Medic product offering

Product offering

Core offering

Oligo Medic develops and commercializes chitosan-based biopolymer medical devices for orthopedic applications. Its marketed product, JointRep®, is an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. The company's pipeline includes LOMU®, a viscosupplementation formulation intended as a longer-residence-time alternative to hyaluronic acid injections for joint lubrication.

Product overview

Oligo Medic is a biomaterials company specializing in orthopedic applications of biopolymers, founded in 2010. The company offers a portfolio centered on chitosan-based technologies for cartilage repair and joint lubrication. The core marketed product is JointRep®, an injectable hydrogel scaffold for cartilage repair, while LOMU® is a pre-clinical viscosupplementation formulation. Underlying these products are proprietary technology platforms including Self-Healing Gel, Nanoparticles (for drug delivery), Photocuring, and Bio-ink, all built on chitosan biopolymer chemistry. The company operates across more than 30 countries through a commercialization network.

Differentiator

Problem solved

Functional benefit

Brands

  • JointRep: Arthroscopically injectable hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedure for cartilage repair. Approved for use by Therapeutic Goods Administration in Australia and multiple other countries. Not currently available in the United States.
  • LOMU

Products and services

  • JointRep®

Quantifiable outcome

  • Cartilage defects occur in more than 900,000 injuries per year in the US alone
  • +1 more outcomes

Companies that use Oligo Medic

Customer profile

Named customers8 records

Segments3 records

Ideal customer profiles2 records

Oligo Medic technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Oligo Medic partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Oligo Medic competitors and assessment

Company assessment

Direct peers

  • Anika Therapeutics: Anika produces hyaluronic acid-based viscosupplementation products (e.g., Monovisc, Orthovisc) for osteoarthritis joint lubrication. Direct competitor to Oligo Medic's pipeline LOMU® product, which is positioned as an alternative to HA injections.
  • Bioventus: Bioventus markets DUROLANE and other HA-based viscosupplements for osteoarthritis treatment, plus orthopedic biologics for cartilage repair. Direct competitor across Oligo Medic's viscosupplementation and cartilage repair portfolio.
  • CartiHeal (Smith & Nephew): CartiHeal (acquired by Smith & Nephew) developed Agili-C, a cartilage repair scaffold for osteochondral lesions. Direct competitor to JointRep® in the cartilage regeneration scaffold market.
  • Ferring Pharmaceuticals: Ferring markets EUFLEXXA (hyaluronic acid viscosupplement) for osteoarthritis knee pain. Direct competitor in the viscosupplementation space that LOMU® would target.
  • Vericel Corporation: Vericel markets MACI (autologous chondrocyte implantation), the leading FDA-approved cartilage repair product. Direct competitor to Oligo Medic's JointRep® in the cartilage repair market, though addressing different procedural approaches (cell therapy vs. hydrogel scaffold-enhanced microfracture).

Broad incumbents

  • Smith & Nephew: Smith & Nephew is a major orthopedic medical device company with products across cartilage repair, sports medicine, and viscosupplementation. Their Regenaflex (hyaluronic acid) and broader sports medicine portfolio overlap with both JointRep® and LOMU® markets.
  • Stryker Corporation: Stryker is a diversified orthopedic medical device leader with sports medicine and joint preservation products relevant to cartilage repair procedures. Larger incumbent operating broadly across Oligo Medic's target orthopedic segments.
  • Sanofi (Genzyme): Sanofi markets Synvisc/Synvisc-One, one of the most widely used HA viscosupplementation brands globally. As a large incumbent in viscosupplementation, Sanofi represents the dominant commercial competitor that LOMU® would need to displace.

Peers

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Oligo Medic social profiles

Digital presence

Oligo Medic compliance and trust

Trust signal

Compliance1 record

Oligo Medic financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Oligo Medic leadership team

Management profile

Number of profiles

Profiles11 records

Oligo Medic funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Oligo Medic M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oligo Medic

What does Oligo Medic do?

Oligo Medic develops and commercializes chitosan-based biopolymer medical devices for orthopedic applications. Its marketed product, JointRep®, is an arthroscopically injectable thermo-gel hydrogel scaffold designed to enhance outcomes of bone marrow stimulation procedures for cartilage repair. The company's pipeline includes LOMU®, a viscosupplementation formulation intended as a longer-residence-time alternative to hyaluronic acid injections for joint lubrication.

Is Oligo Medic a public or private company?

Oligo Medic is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Oligo Medic founded?

Oligo Medic was founded in 2010. It employs 1 to 10 people.

Where is Oligo Medic based?

Oligo Medic is headquartered in Montreal, Canada, in the North America region.

How does Oligo Medic make money?

Three revenue lines are on record. Medical Device Product Sales are the primary driver. The others are LOMU® Viscosupplementation (Pipeline) and technology Licensing.

Who are Oligo Medic's main competitors?

Direct peers on record are Anika Therapeutics, Bioventus, CartiHeal (Smith & Nephew), Ferring Pharmaceuticals and Vericel Corporation. Broad incumbents are Smith & Nephew, Stryker Corporation and Sanofi (Genzyme). Histogenics (now part of Ocugen) is listed as a peer.

Does Oligo Medic have an API?

No public API is recorded for Oligo Medic.

What industry is Oligo Medic in?

Oligo Medic's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials), with a secondary code of HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AffarsvarldenEpisurf vill avyttra medicinteknisk verksamhetEpisurf Medical has entered into a letter of intent with Canadian Oligo Medic to sell its medical technology business. The deal is part of Episurf's refocusing on real estate, and the parties will now work on the transaction structure and a final agreement.news.cision.comEpisurf Medical has entered into a letter of intent with Oligo Medic regarding the divestment of the medical technology businessEpisurf Medical entered a letter of intent with Oligo Medic to divest its medical technology business, which includes the Episealer implant and Epiguide instruments. The deal is part of Episurf's refocusing on property operations, with no transaction completed yet.BioSpaceOligo Medic Appoints Dr. Marie-Lyne Nault as Chief Medical OfficerOligo Medic appointed Dr. Marie-Lyne Nault as Chief Medical Officer, a Harvard-trained pediatric orthopedic surgeon. The move supports its joint preservation focus, building on JointRep's success. The company plans to expand into a full spectrum of joint-preservation care.NewswireOligo Medic Appoints Dr. Marie-Lyne Nault as Chief Medical OfficerOligo Medic appointed Dr. Marie-Lyne Nault as Chief Medical Officer, a Harvard-trained pediatric orthopedic surgeon. The move supports its joint preservation mission, building on its flagship product JointRep, an injectable biomaterial scaffold for cartilage lesions. The company aims to expand into a full spectrum of joint-preservation care.PR NewswireOligo Medic Appoints Jerett Creed As CEOOligo Medic announced the appointment of Jerett A. Creed as Chief Executive Officer on May 9, 2017. Creed brings over 20 years of medtech experience with a track record spanning international commercialization and capital markets, including M&A transactions exceeding $650 million. Most recently, he was responsible for launching Oligo Medic's JointRep™ product throughout Latin America, suggesting a strategic focus on international expansion under his leadership.PR NewswireOsteoartritis:Pacientes con pérdida de cartílago avanzada podrían no someterse a una sustitución de rótula totalOligo Medic Inc., a Canadian medical device company, published six-month clinical trial results showing that its JointRep™ product combined with microfracture treatment significantly outperformed microfracture alone in repairing knee cartilage damage. The trial of 60 patients aged 18-75 demonstrated an 88% improvement in WOMAC scores for the JointRep™ group versus 40% for the control group, with rehabilitation time reduced from 8 weeks to 2 weeks. JointRep™ holds CE marking and is currently distributed in 15 countries but is not yet available in North America.PR NewswireArthrose: Tausende von Patienten, die an fortgeschrittenem Knorpelverlust leiden, können möglicherweise auf künstliches Kniegelenk verzichtenOligo Medic Inc., a Canadian medical device company, announced positive 6-month clinical results from a controlled post-market study of its JointRep™ cartilage repair product, showing an 88% average improvement in WOMAC scores compared to 40% for microfracture treatment alone. The study of 60 patients aged 18-75 with Grade III-IV cartilage lesions demonstrated that JointRep™ combined with microfracture reduced rehabilitation time from 8 weeks to 2 weeks while enabling same-day discharge. The CE-marked product is currently available in 15 countries but not yet in North America.PR NewswireOstéoarthrite: Des milliers de patients souffrant de perte de cartilage importante pourraient ne pas avoir à subir une arthroplastie complète du genou (c'est-à-dire la pose d'une prothèse)Oligo Medic Inc., a Canadian medical device company, published 6-month clinical trial results for JointRep™, an injectable polyglucosamine hydrogel matrix used alongside microfracture surgery to repair cartilage lesions in knee joints.